- Home
- Companies
- BioLingus AG
- Articles
- Project - Sublingual IL2 (BL SLIT I)
Project - Sublingual IL2 (BL SLIT I)
Courtesy of BioLingus AG
The aim of this project is to develop low dose IL-2 for treatment of early onset juvenile Type I diabetes. Low dose injectable IL-2 in animal models has been shown to restore the balance between regulatory and effector T cells and, in this way, can help to reverse autoimmunity and the development of type I diabetes. Looking ahead, we anticipate that having a suitable oral formulation of IL-2 to use in children with recent onset type I diabetes will be important.
Once the proof of concept has been achieved for type I diabetes, we expect that sublingual IL-2 can be further developed for a range of other autoimmune/allergic disorders, all of which are likely to benefit from restoring the balance between regulatory and effector T cell.
These diseases include:
- Asthma
- Psoriasis
- Lupus
- Rheumatoid arthritis
- Multiple sclerosis
-
Most popular related searches
Customer comments
No comments were found for Project - Sublingual IL2 (BL SLIT I). Be the first to comment!